Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Continues To Bet On Alzheimer's With Avid Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Unfazed by recent setbacks to semagacestat, Eli Lilly pays $300 million upfront to acquire a diagnostic company with a promising late-stage test for Alzheimer's disease.

You may also be interested in...



Merck Partners On Alzheimer’s Diagnostic With GE Healthcare

Merck will use GE Healthcare’s investigational imaging agent flutemetamol to select patients to enroll in its clinical trial studying the oral BACE inhibitor MK-8931, with a particular emphasis on a future study in Alzheimer’s patients with mild cognitive impairment.

Lilly Gains Amyvid Approval, But Reimbursement Still A Hurdle

Lilly’s Avid has gained approval for its imaging agent Amyvid, a new tool in the Alzheimer’s disease diagnosis arsenal.

Medicare Coverage For Amyvid Complicated By PET Policy; Lilly Seeks Revision

Under CMS’ current policy for PET scans, new imaging agents approved by FDA would have to go through a national coverage analysis before Medicare will pay for them.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel